A Mayo Clinic study suggests postmenopausal women lost 35% more weight combining hormone therapy with tirzepatide, though ...

DENVER — Postmenopausal women who receive hormone therapy show significantly greater weight loss when treated with the glucagon-like peptide 1 (GLP-1) receptor agonist drug semaglutide than those who ...

When trying to lose weight, many people focus on a basic “calories in versus calories out” model. Yes, nutrition and energy expenditure are certainly important considerations when pursuing weight loss ...

SAN FRANCISCO—Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with overweight or obesity compared to use of tirzepatide ...

Did our AI summary help? For many women, menopause brings more than just hot flashes. Sometimes, it also brings unwanted weight gain. A recent study led by the Mayo Clinic reveals that combining ...

When the scale refuses to budge despite your best efforts at diet and exercise, the answer might lie deeper than calories in versus calories out. Your hormones could be working against you in ways you ...

A new study led by Mayo Clinic found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide, a Food and Drug Administration-approved drug for the ...

(Halfpoint Images/Moment/Getty Images) Scientists have uncovered a potential drug combo that may supercharge popular ...

Conversations around menopause and perimenopause include an array of symptoms and how to manage them. Each woman responds ...

Metformin raised the exercise-linked metabolite Lac-Phe in prostate cancer patients across disease stages and treatment ...

Imbalances in certain hormones, such as cortisol, thyroid hormones, insulin, and others, can link to childhood obesity. However, factors such as diet and physical activity levels more often lead to ...